Iguana Healthcare Management LLC Invests $905,000 in Amicus Therapeutics, Inc. (FOLD) Stock

Iguana Healthcare Management LLC bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $905,000.

Other institutional investors also recently made changes to their positions in the company. Strs Ohio bought a new stake in Amicus Therapeutics during the third quarter worth approximately $102,000. Birchview Capital LP bought a new stake in Amicus Therapeutics during the third quarter worth approximately $151,000. Teacher Retirement System of Texas boosted its position in Amicus Therapeutics by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares during the period. Engineers Gate Manager LP bought a new stake in Amicus Therapeutics during the third quarter worth approximately $155,000. Finally, Tudor Investment Corp ET AL bought a new stake in Amicus Therapeutics during the second quarter worth approximately $124,000.

FOLD has been the subject of a number of recent analyst reports. J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Chardan Capital reaffirmed a “buy” rating and set a $16.50 target price (down previously from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday, September 13th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Tuesday, October 10th. Cowen reaffirmed an “outperform” rating and set a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, September 14th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $17.81.

In related news, CEO John F. Crowley sold 449,295 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. Following the completion of the transaction, the chief executive officer now directly owns 380,723 shares of the company’s stock, valued at $5,455,760.59. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the transaction, the insider now directly owns 69,184 shares of the company’s stock, valued at $940,210.56. The disclosure for this sale can be found here. Insiders sold 692,643 shares of company stock valued at $9,899,547 over the last three months. 3.40% of the stock is owned by company insiders.

Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $12.90 on Friday. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same period in the prior year, the company posted ($0.33) earnings per share. The firm’s revenue was up 419.0% compared to the same quarter last year. analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://sportsperspectives.com/2017/12/15/iguana-healthcare-management-llc-invests-905000-in-amicus-therapeutics-inc-fold-stock.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply